Data For New Alzheimer’s Disease Treatment For Agitation To Be Presented at Upcoming ANA Meeting

Data For New Alzheimer’s Disease Treatment For Agitation To Be Presented at Upcoming ANA Meeting
agitation drug for Alzheimer'sAvanir Pharmaceuticals, Inc. will present their most-recent results from two clinical trials currently underway for treating conditions associated with Alzheimer's disease (AD). The data is set to be presented at the American Neurological Association's (ANA) Annual Meeting in Baltimore, Maryland, from October 12-14, 2014. The phase II clinical trial evaluated AVP-923 safety, tolerability, and efficacy for the treatment of agitation in Alzheimer's patients. Agitation is associated with a faster cognitive decline in these patients and poses a serious distress factor for patients, families, and caregivers. The trial was performed over the course of 10 weeks, and included 220 Alzheimer's patients from the United States treated with increasing doses of AVP-293 compared to placebo-administrated patients. The placebo group was evaluated at week 5 and administered with either the same placebo treatment or with AVP-293 for the remaining trial period. The efficacy of the study was determined according to the agitation/aggression response measured in agreement with the Neuropsychiatric Inventory (NPI). Additional outcomes analyzed included disease severity, further neuropsychiatric symptoms, cognition, daily living activity, quality of life and caregiver strain. The second clinical trial, PRISM II, evaluated NUEDEXTA safety, tolerability, and efficacy to treat PseudoBulbar affect (PBA) in patients with neurologic disorders, including Alzheimer's d
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *